# Tim Sweeney

> Tim Sweeney is the co-founder and CEO of Inflammatix, a Sunnyvale molecular diagnostics company that reads the immune system instead of hunting for pathogens. A surgeon-turned-entrepreneur with an MD/PhD from Duke and a biomedical informatics background from Stanford, he built TriVerity, an FDA-cleared rapid blood test that measures 29 immune-response genes and uses machine learning to score the likelihood of bacterial infection, viral infection, and severe illness. He has raised more than $200 million to bring precision medicine to sepsis and critical care.

- **Role:** Co-Founder and CEO at Inflammatix, Inc.
- **Organizations:** Inflammatix, Inc., Sepsis Alliance (Board of Directors), Stanford University (former)
- **From:** Colorado, United States
- **Nationality:** American
- **Education:** BA Biology, BA Chemistry, BS Biological Chemistry, University of Chicago, MD and PhD, Duke University, Surgical residency; postdoctoral MS in Biomedical Informatics, Stanford University
- **Known for:** Co-founded and leads Inflammatix, raising more than $200 million in venture and non-dilutive government funding (BARDA, DARPA, NIH), Brought TriVerity, a first-in-class FDA-cleared host-response blood test, from research idea to clinically validated product, Co-invented an immune-reading diagnostic approach exclusively licensed from Stanford University

## Career timeline

- **2011** — Began general surgery residency at Stanford after MD/PhD at Duke
- **2011-2015** — Surgery resident at Stanford; completed postdoctoral MS in Biomedical Informatics under Dr. Purvesh Khatri
- **2015-2017** — Research Associate at Stanford's Institute for Immunity, Transplantation and Infection
- **2016** — Co-founded Inflammatix with Purvesh Khatri and Jonathan Romanowsky to commercialize host-response diagnostics
- **2024** — Inflammatix closed a Series E financing; total funding surpassed $200M
- **2025-01** — TriVerity received FDA 510(k) clearance as a first-in-class host-response test
- **2025-09** — Inflammatix published three landmark papers in Nature Medicine on acute infection and sepsis

## Achievements

- Co-founded and leads Inflammatix, raising more than $200 million in venture and non-dilutive government funding (BARDA, DARPA, NIH)
- Brought TriVerity, a first-in-class FDA-cleared host-response blood test, from research idea to clinically validated product
- Co-invented an immune-reading diagnostic approach exclusively licensed from Stanford University
- Oversaw 60+ clinical studies across thousands of patients on four continents
- Co-authored three landmark Nature Medicine publications redefining sepsis diagnosis and treatment (2025)
- Appointed to the Sepsis Alliance Board of Directors
- Widely cited physician-scientist in host-response transcriptomics and computational immunology

## Latest updates

- **2025-09** — Inflammatix announced three landmark Nature Medicine publications redefining acute infection and sepsis diagnosis and treatment.
- **2025-01** — TriVerity received FDA 510(k) clearance as a first-in-class host-response diagnostic test.
- **2024-09** — Company completed a Series E financing round; cumulative funding passed $200 million.

## Links

- Website: https://inflammatix.com
- LinkedIn: http://www.linkedin.com/in/tim-sweeney-a6589594

---

Profile page: https://yespress.io/tim-sweeney
Published by YesPress — https://yespress.io
Last updated: 2026-06-04